Billing codes used to seek reimbursement for Hizentra, including supplies, pump and nursing, for a primary immunodeficiency disease
When choosing a site of care for immune globulin therapy, each patient’s unique situation needs to be considered.
Reimbursement rates for infusion medications; reimbursement process for infusion centers; and what to do if when employer carrier changes result in denied coverage.
Exploring the new ICD-9 code for acquired hemophilia and Medicare reimbursement for in-home nursing services.
Addressing questions regarding reimbursement for subcutaneous immune globulin in patients with primary immunodeficiency.
The drug shortage crisis has been referred to as “a tsunami of medical risk,” and there is no sign that the problem will disappear in the near future.
Several advocacy groups are focusing their efforts on reimbursement issues that they believe threaten patients’ access to care.
A high-cost therapy coupled with a complex and evolving reimbursement model has created what some are calling a healthcare crisis for tens of thousands of chronically ill patients.
Some commonly held misunderstandings about reimbursement are clarified, including reimbursement for IVIG, SCIG, affordability and assistance.
Clearing up common misunderstandings about reimbursement rates for subcutaneous immune globulin therapy and vaccine costs.
Modifications in the steps and ingredients of the manufacturing process of immune globulin have changed the world of immune therapy.
The healthcare reform laws include new strict reporting guidelines for the medical industry, and physicians need to ensure that what is reported is correct to protect their practice.